期刊
ACTA BIOMATERIALIA
卷 9, 期 6, 页码 7064-7073出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2013.02.040
关键词
Mesoporous; Titanium; Drug delivery; Bisphosphonate; Raloxifene
资金
- Materials Area of Advance at Chalmers University of Technology
- University of Gothenburg, BIOMAT-CELL VINN Excellence Center of Biomaterials and Cell Therapy
- Swedish Research Council [K2012-52X-09495-25-3, B0603701]
This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据